Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1Head & Neck 1Gynecologic 1Genitourinary 1Dermatologic 1Breast 1

Conditions

Primary Myelofibrosis 3Myeloproliferative Disorders 3Pancreatic Neoplasms 2Lymphoma, Non-Hodgkin 2Lung Neoplasms 2Thrombocytosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Melanoma 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Leukemia, Prolymphocytic, T-Cell 1Leukemia, Myeloid, Acute 1Inhibition, Psychological 1Hodgkin Disease 1Head and Neck Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1B-cell Malignancies 1B-Cell Malignancies 1

Interventions

Gemcitabine 358Fluorouracil 94Oxaliplatin 81Capecitabine 74130-nm albumin-bound paclitaxel 71Albumin-Bound Paclitaxel 70Radiotherapy 67Leucovorin 58Irinotecan 49Erlotinib Hydrochloride 47Cisplatin 44Bevacizumab 31pembrolizumab 30Radiosurgery 30Docetaxel 26Taxes 24Nivolumab 24Cetuximab 24Pancreaticoduodenectomy 20Drug Therapy 17folfirinox 16Cyclophosphamide 16Radiation 15Ipilimumab 13Endoscopic Ultrasound-Guided Fine Needle Aspiration 13Surgical Procedures, Operative 12Sorafenib 12Paclitaxel 12Neoadjuvant Therapy 12irinotecan sucrosofate 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Pancreatic Neoplasms × itacitinib × Clear all
NCT02646748 2022-03-31

Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors

Incyte Corporation

Phase 1 Completed
159 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Breast Neoplasms, Carcinoma, Renal Cell, Head and Neck Neoplasms, Lung Neoplasms, Melanoma, Pancreatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT01858883 2019-07-18

Safety Study of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors

Incyte Corporation

Phase 1/2 Completed
55 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡